Logo image of JUNS

JUPITER NEUROSCIENCES INC (JUNS) Stock Price, Quote, News and Overview

NASDAQ:JUNS - Nasdaq - US48208B2034 - Common Stock - Currency: USD

0.7  +0.01 (+2.19%)

After market: 0.7 0 (0%)

JUNS Quote, Performance and Key Statistics

JUPITER NEUROSCIENCES INC

NASDAQ:JUNS (2/26/2025, 6:39:39 PM)

After market: 0.7 0 (0%)

0.7

+0.01 (+2.19%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap23.17M
Shares33.10M
Float15.16M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-03 2024-12-03


JUNS short term performance overview.The bars show the price performance of JUNS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

JUNS long term performance overview.The bars show the price performance of JUNS in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of JUNS is 0.7 USD. In the past month the price decreased by -47.05%.

JUPITER NEUROSCIENCES INC / JUNS Daily stock chart

JUNS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 70.39 868.64B
NVO NOVO-NORDISK A/S-SPONS ADR 27.81 397.52B
JNJ JOHNSON & JOHNSON 16.32 392.63B
AZN ASTRAZENECA PLC-SPONS ADR 20.92 234.20B
MRK MERCK & CO. INC. 11.7 226.10B
NVS NOVARTIS AG-SPONSORED ADR 13.6 213.35B
PFE PFIZER INC 8.5 149.72B
SNY SANOFI-ADR 13.67 137.77B
BMY BRISTOL-MYERS SQUIBB CO 50.33 116.38B
GSK GSK PLC-SPON ADR 7.94 76.32B
ZTS ZOETIS INC 27.87 74.44B
TAK TAKEDA PHARMACEUTIC-SP ADR 32.59 45.46B

About JUNS

Company Profile

Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which of it primarily is targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, the Company is primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100 milligrams (mg) of resveratrol. The company has a worldwide license, from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

Company Info

JUPITER NEUROSCIENCES INC

1001 North US HWY 1, Suite 504

Palm Beach Gardens FLORIDA US

Employees: 4

Company Website: https://jupiterneurosciences.com/

Phone: 15614066154

JUPITER NEUROSCIENCES INC / JUNS FAQ

What is the stock price of JUPITER NEUROSCIENCES INC today?

The current stock price of JUNS is 0.7 USD. The price increased by 2.19% in the last trading session.


What is the ticker symbol for JUPITER NEUROSCIENCES INC stock?

The exchange symbol of JUPITER NEUROSCIENCES INC is JUNS and it is listed on the Nasdaq exchange.


On which exchange is JUNS stock listed?

JUNS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for JUPITER NEUROSCIENCES INC stock?

7 analysts have analysed JUNS and the average price target is 30.6 USD. This implies a price increase of 4271.43% is expected in the next year compared to the current price of 0.7. Check the JUPITER NEUROSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is JUPITER NEUROSCIENCES INC worth?

JUPITER NEUROSCIENCES INC (JUNS) has a market capitalization of 23.17M USD. This makes JUNS a Nano Cap stock.


How many employees does JUPITER NEUROSCIENCES INC have?

JUPITER NEUROSCIENCES INC (JUNS) currently has 4 employees.


Should I buy JUPITER NEUROSCIENCES INC (JUNS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does JUPITER NEUROSCIENCES INC (JUNS) stock pay dividends?

JUNS does not pay a dividend.


What is the Price/Earnings (PE) ratio of JUPITER NEUROSCIENCES INC (JUNS)?

JUPITER NEUROSCIENCES INC (JUNS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).


What is the Short Interest ratio of JUPITER NEUROSCIENCES INC (JUNS) stock?

The outstanding short interest for JUPITER NEUROSCIENCES INC (JUNS) is 0.86% of its float. Check the ownership tab for more information on the JUNS short interest.


JUNS Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

JUNS Financial Highlights

Over the last trailing twelve months JUNS reported a non-GAAP Earnings per Share(EPS) of -0.15.


Industry RankSector Rank
PM (TTM) N/A
ROA -5588.43%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%60%
Sales Q2Q%N/A
EPS 1Y (TTM)0%
Revenue 1Y (TTM)-100%

JUNS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to JUNS. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners0.01%
Ins Owners45.71%
Short Float %0.86%
Short Ratio0.05
Analysts
Analysts82.86
Price Target30.6 (4271.43%)
EPS Next Y59.2%
Revenue Next YearN/A